EchoPrime was trained on more than 12 million videos; it’s now being tested clinically, with more data expected next year.

Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.” ...

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

NEW ORLEANS, LA—Complete revascularization in patients presenting with ACS and multivessel coronary artery disease ...

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...